Valneva SE reported €175M of revenue over the trailing twelve months, +3.0% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €175M (to Q4 2025). Net income: −€115M, trailing twelve months to Q4 2025. Free cash flow: −€57M, trailing twelve months to Q4 2025. Operating margin: −55%, trailing twelve months to Q4 2025.

VALNValneva SE

Healthcare

$5.72-48% 1Y

$5.72

$4.7852 weeks$11.99

VALN as reported

Valneva SE reported €175M of revenue over the trailing twelve months, +3.0% on the year before. 10 reported series are charted on this page, each one as filed.

€175M

Revenue, trailing twelve months · to Q4 2025 · +3.0% against the twelve months before

Net income: −€115M
Net income · +841% year on year · trailing twelve months to Q4 2025
Free cash flow: −€57M
Free cash flow · −30% year on year · trailing twelve months to Q4 2025
Operating margin: −55%
Operating margin · trailing twelve months to Q4 2025

Details›

Every series Ryufin has for VALN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€175M	+3.0%	Q4 2025
Net income	−€115M	+841%	Q4 2025
EPS	−€0.68	+750%	Q4 2025
Gross margin	37%	n/a	Q4 2025
Operating margin	−55%	n/a	Q4 2025
Net margin	−75%	n/a	Q4 2025
ROE	−65%	n/a	Q4 2025
ROA	−21%	n/a	Q4 2025
ROIC	−29%	n/a	Q4 2025
Free cash flow	−€57M	−30%	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.